BLS

BLSPHARMA FPO [BLS]

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Healthcare · ASX Small Cap

$1.1100 +0.4%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 3 consecutive scansFirst seen: 2026-07-13

Get alerts when BLS triggers a new signal

Free watchlist with daily scans for 2,200+ ASX stocks

Track BLS — Free

Active Signals

Bullish Signals

MACD momentum is picking up steam
Trading above both moving averages — the trend is your friend here
Volume surging at 3.4x normal while price climbs — real buying conviction behind this move
On a tear — up 20.7% over the last 5 days
Beating the Small Ords index — relative strength of 1.25, so it's outpacing the pack
Volatility is expanding fast — choppy price action, so buckle up
Trading above the 200-day average — the long-term trend is on your side
Cash positive / operating cashflow positive
Moderate P/S ratio (5.2x)
Strong revenue growth (+150%)
Piotroski F-Score strong (8/9, low-confidence approx)
Post-earnings drift: positive surprise (SUE +10)
CANSLIM C: Strong EPS growth (124% QoQ)
CANSLIM N: Near 52-week high (breakout territory)
CANSLIM S: Tight float (32%)
Strong return on equity (66%)
Healthy profit margins (19%)
Sentiment is mixed — no strong consensus either way
Strong long-term momentum — up 133% over the past year (excluding last month)
Excellent risk-adjusted returns — Sharpe of 2.0 means strong gains without wild swings
Earnings are trending the right way — 2 consecutive improvements
Revenue growing at +150% — the top line is moving in the right direction
The bigger volume days are the up days — volume-weighted momentum is positive (2.40%/day)
RBA hiking (-3pts)

Risk Signals

RSI is running hot — overbought territory, so expect some pullback risk
RSI is overbought but volume confirms it — this could be genuine momentum, not just froth
Not enough chatter to gauge sentiment — defaulting to neutral

Ask Scout AI about BLS

"What's driving BLS today?" "How does BLS compare to peers?" "Key risks for BLS?"

3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4G Corporate Governance Statement

NONE BLS FY2027 Guidance

NONE BLS FY2026 Results Announcement

LOW BLS Investor Presentation

LOW Annual Report to shareholders

Recent ASX Announcements

2026-08-31	Appendix 4G Corporate Governance Statement
2026-08-31	BLS FY2027 Guidance PRICE SENSITIVE
2026-08-31	BLS Investor Presentation PRICE SENSITIVE
2026-08-31	BLS FY2026 Results Announcement PRICE SENSITIVE
2026-08-31	Annual Report to shareholders PRICE SENSITIVE

Key Metrics

$249.9M

Market Cap

310K

Avg Volume

3.4x

Vol Ratio

$0.33 — $1.20

52-Week Range

0.0%

Short Interest

N/A

Cash Runway

66.1%

ROE

18.7%

Profit Margin

CANSLIM Analysis

	Factor	Rating	Detail
C	Current EPS	pass	EPS Growth: 124%
A	Annual Earnings	fail	CAGR: 0%
N	New Highs / Catalysts	pass	Near 52w High
S	Supply & Demand	pass	Float: 32%
L	Leader vs Laggard	pass	RS: 14
I	Institutional Sponsorship	weak	Inst: 1%
M	Market Direction	neutral	Neutral